Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NF7DRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTJfnI2yqEQvF2= M3nMZlQ5yqCq NHvOXW1jdG:la4OgNlcuV0iFLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHPvcZBiemGkbHWgeI8hfGijdDDv[kBj[XOjbDDs[ZZmdHN? MojtNlY{PTB3NkW=
NP69 M13VWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNzLk[5xtEzNjV2IN88US=> MWqyOlI2OjV5NR?=
NP460 NWLV[ItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ{Lki1xtEyNjF6IN88US=> NGfFPJczPjJ3MkW3OS=>
C666-1 NF;acG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHewRnNKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? M{TFUVI3OjV{NUe1
C666-1 NUXjV4lDS2WubDDWbYFjcWyrdImgRZN{[Xl? MmG0NVAhyrWP NEHYWFk1QCCq NIDSRoRFVVOR MnLYd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw MljlNlYzPTJ3N{W=
C666-1  MlroSpVv[3Srb36gRZN{[Xl? MmL0NVAhyrWP MlXUNlQhcA>? MX;EUXNQ MWDhZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> MVGyOlI2OjV5NR?=
C666-1 MlvpRZBweHSxc3nzJGF{e2G7 M4jGS|ExKML3TR?= NXjjOGx3PDhxN{KgbC=> M2exfWROW09? NYPEOIlwe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8h[2m|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MlTmNlYzPTJ3N{W=
A549 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PvWFI1KGh? M3u5[WlEPTB;MUeuOlghyrFiND61NkDPxE1? MWGyOlEzPTJ|MB?=
A549-NTC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TWdlI1KGh? NUfnNGxbUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= MoDmNlYyOjV{M{C=
A549-920 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnoTY5nOjRiaB?= MkSwTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? M{\XUlI3OTJ3MkOw
CRL-5908 M3rtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vWflI1KGh? NWfwdnF4UUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?= NFjwWpkzPjF{NUKzNC=>
L6 NV7HdnlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn5N3ZwOTEEoN88UeKh M2XKdlI1NzR6L{eyJIg> NVPu[W9jTE2VTx?= NFrXNYFqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? M1X6S|I2QDdzN{m0
C2C12 NUnOWoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTENVDDqM7:TdMg NGL2RZAzPC92OD:3NkBp Mn3OSG1UVw>? MWDpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> Ml;nNlU5PzF5OUS=
MCF-7  NGWzTXpHfW6ldHnvckBCe3OjeR?= MVyxNOKh|ryP MkTqSG1UVw>? M{Lq[4lvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? NV[1d3ZQOjV5MEK3NFM>
DU4475  Ml\mSpVv[3Srb36gRZN{[Xl? M3vzNlUwOTBxMkCg{txO NWW1[WNOOjUEoHi= NITudlFld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NXHCb2ZDOjV3NEexO|Q>
SMMC-7721 NX7vUlhOTnWwY4Tpc44hSXO|YYm= MUexNEDPxE1? M{jhZ|Q5KGh? M1L5TmROW09? Mn\yZ4F2e2W|IFTORUBFW0JiZHHtZYdm NEmwbm8zPTV2NEO2NS=>
SMMC-7721 NHvhXoVHfW6ldHnvckBCe3OjeR?= NGXZc28yOCEQvF2= M1TlZVQ5KGh? M3fvd2ROW09? NFLSbmFqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh MX:yOVU1PDN4MR?=
SMMC-7721 Ml;tSpVv[3Srb36gRZN{[Xl? M3XSclExKM7:TR?= NF;qbnI1QCCq MX\EUXNQ MXrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B MU[yOVU1PDN4MR?=
SMMC-7721 MXfGeY5kfGmxbjDBd5NigQ>? M2PPXVExKM7:TR?= MWWzOkBp M3vtZ2ROW09? NU\iVHRl[2G3c3XzJJRp\SCnY4TvdIlkKGW6cILld5Nqd25ib3[gTWZKOTZ? NYnjS5Z6OjV3NESzOlE>
MCF-7 MYfGeY5kfGmxbjDBd5NigQ>? M2TKZlExyqEQvF2= NFHUfWMxNTJ2IHi= NILkbGlqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= MW[yOVQ5OjN5Mx?=
OVCAR10 NYW2bYtqTnWwY4Tpc44hSXO|YYm= MUmxNOKh|ryP M{nHcFIycMLi M1zvS2ROW09? M3rYU4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> NV6w[Fk4OjV2Mk[1OFg>
NCI-H23 M{ThR2Z2dmO2aX;uJGF{e2G7 M1TCNlExyqEQvF2= NEHEUVkzOWkEoB?= MYjEUXNQ NYC1WGZ7cW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? Mn71NlU1OjZ3NEi=
A2780 NX72OlFrTnWwY4Tpc44hSXO|YYm= M1S0OVExyqEQvF2= NIDTVZYzOWkEoB?= NVfESIlnTE2VTx?= MkTybY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MVqyOVQzPjV2OB?=
NCI-H23 NYjSe|c3TnWwY4Tpc44hSXO|YYm= NVTDPWxkOTEEoN88US=> MkjRNlFpyqB? NFT1W|NFVVOR NVexeVRN\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> NVzEV3R7OjV2Mk[1OFg>
A2780 M4OxdGZ2dmO2aX;uJGF{e2G7 NUXMNZpFOTEEoN88US=> MnX5NlFpyqB? NW\sZ2ZFTE2VTx?= M{jKWYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz NX;wTFNEOjV2Mk[1OFg>
HCT116  Ml\hSpVv[3Srb36gRZN{[Xl? M1LPNlExKML3TR?= MoD5NlQhcA>? MmXyZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 MmGxNlU{QDByNUW=
MCF-10CA1a M1T1PGZ2dmO2aX;uJGF{e2G7 MXyxNOKh|ryP MnX3OFghcA>? M1HEZWROW09? M3L4eIlvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? MkjINlUzPTd5Mkm=
MCF-10A1  NWXX[pZGTnWwY4Tpc44hSXO|YYm= MX:xNOKh|ryP MlL1NlQwPDhiaB?= M{ThNWROW09? MkLFbY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh MljXNlUzPTd5Mkm=
MCF-10CA1a Mlm1SpVv[3Srb36gRZN{[Xl? NYD5dXN[OTEEoN88US=> NYPwbG5NOjRiaB?= Mm\LSG1UVw>? MYPk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? M130XlI2OjV5N{K5
MCF-10CA1a NVm4UXFQTnWwY4Tpc44hSXO|YYm= NV:2[2dJOTEEoN88US=> NXflWJhrOjRiaB?= MnHPSG1UVw>? MWDpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MWOyOVI2Pzd{OR?=
SK-BR-7 NFfLUVhHfW6ldHnvckBCe3OjeR?= NH73Z3YyOMLizszN Mo\uNlQhcA>? MUjEUXNQ M1PMS4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MnznNlUzPTd5Mkm=
SUM102PT NYjUc5huTnWwY4Tpc44hSXO|YYm= NUHVOGF1OTEEoN88US=> NFS2NnozPCCq NUDNc|g2TE2VTx?= MknrbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M{jrS|I2OjV5N{K5
RAW 264.7 M4HK[WZ2dmO2aX;uJGF{e2G7 MYexNOKh|ryP MlvZN|AhdWmw NWrXeXJJeHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU MX[yOVE4OjV2Nx?=
RAW 264.7 MY\GeY5kfGmxbjDBd5NigQ>? NFiyWFYyOMLizszN M2\U[FMxKG2rbh?= MX;y[YR2[2W|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7 M1jGd|I2OTd{NUS3
RAW 264.7 NUPLcWw1TnWwY4Tpc44hSXO|YYm= MUmxNOKh|ryP NV\PZo1POzBibXnu NFP6OppqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> NIHkXXkzPTF5MkW0Oy=>
MCF7  MnfCR4VtdCCYaXHibYxqfHliQYPzZZk> NUXlTGs{Oi53INM1US=> NI\US3E2KGR? M3r0TGROW09? M4TJTpNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= NXu2VoNoOjVyOEW5NFI>
MCF7  NYq0dXdrTnWwY4Tpc44hSXO|YYm= M{n5ZlIvPSEEtV2= MVe0PEBp NWL2UFZQTE2VTx?= M2rNe4Rm[3KnYYPld{B1cGViaH;tc4xw\2:3czDEV2IhemWyYXnyJIZz\XG3ZX7jbYV{ MXWyOVA5PTlyMh?=
ACHN NV3rZmg3S2WubDDWbYFjcWyrdImgRZN{[Xl? MXiwMlUuOTBizszN MoD6NE03KGR? NEi4TW9FVVOR MlTDbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2SzW|I2ODZ5N{i3
Caki-2 NGLR[XdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXvM[YN{OC53LUGwJO69VQ>? M2Hs[lAuPiCm MnrWSG1UVw>? M1P3TYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWiyOVA3Pzd6Nx?=
A498 NV7mc2hDS2WubDDWbYFjcWyrdImgRZN{[Xl? NVHMOFVLOC53LUGwJO69VQ>? MmnnNE03KGR? MVjEUXNQ NVzHPY5ScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHLQbWEzPTB4N{e4Oy=>
115 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnO1NE42NTFyIN88US=> MUGwMVYh\A>? M{TyUmROW09? NVHn[JdmcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1TSeFI2ODZ5N{i3
117 M4fFVWNmdGxiVnnhZoltcXS7IFHzd4F6 NGL0elUxNjVvMUCg{txO NH7JOIoxNTZiZB?= NFLjOINFVVOR NEnZ[45qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWTvXJM4OjVyNke3PFc>
ACHN MWrGeY5kfGmxbjDBd5NigQ>? Mom1NE42NzFxNTFOwG0> NXnrfo01PDhiaB?= MUfEUXNQ NUj5UndYdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NXLsWHRROjVyNke3PFc>
Caki-2 NUiyZo11TnWwY4Tpc44hSXO|YYm= NGfsNpgxNjVxMT:1JO69VQ>? NYXQToE5PDhiaB?= MkT2SG1UVw>? NEDBd|Rt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NXrrdoE2OjVyNke3PFc>
A498 MoG0SpVv[3Srb36gRZN{[Xl? NVzkS5VTOC53L{GvOUDPxE1? M2TlN|Q5KGh? MYLEUXNQ MXjs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NFjvfFYzPTB4N{e4Oy=>
115 MUDGeY5kfGmxbjDBd5NigQ>? MYewMlUwOS93IN88US=> NI\lSlA1QCCq NF3aRnZFVVOR MlvCcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NXTGRWZIOjVyNke3PFc>
ACHN NELsXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPBR4pDPSEQvF2= NF3MNZk1QCCq MkO1SG1UVw>? MkS4bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MXmyOVA3Pzd6Nx?=
Caki-2 NXrLRYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS1JO69VQ>? NFXGdWQ1QCCq M4\ZNWROW09? M1jRN4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NH[5eoMzPTB4N{e4Oy=>
A498 NVW3d5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjCOUDPxE1? Mle5OFghcA>? Mlr1SG1UVw>? MY\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= MUmyOVA3Pzd6Nx?=
115 NG\HOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDCOUDPxE1? M{\JelQ5KGh? NEPZRXZFVVOR NIf0WI9qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M1TNbFI2ODZ5N{i3
ACHN NH62RW9HfW6ldHnvckBCe3OjeR?= MUO1JO69VQ>? NFPl[IE1QCCq MVfEUXNQ MlvNbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= M4jHe|I2ODZ5N{i3
Caki-2 MXPGeY5kfGmxbjDBd5NigQ>? NYr2RZlGPSEQvF2= MnXIOFghcA>? M33FcmROW09? NIrvOZVqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NEP3eHUzPTB4N{e4Oy=>
A498 Mk\4SpVv[3Srb36gRZN{[Xl? MWG1JO69VQ>? MX:0PEBp Mm\BSG1UVw>? MY\pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NEfROoIzPTB4N{e4Oy=>
115 NG[zUFNHfW6ldHnvckBCe3OjeR?= NEDZPVk2KM7:TR?= MXi0PEBp NXjSXXFnTE2VTx?= NFXBV5lqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg Mn3RNlUxPjd5OEe=
MOLM-13 M{LyZmZ2dmO2aX;uJGF{e2G7 NYTuUFk3PsLizszN MnezNE05KGh? M3ixW2ROW09? NYDOXVh5cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| M{TOSFI1QDh3MEiy
MOLM-13 MVvGeY5kfGmxbjDBd5NigQ>? NFfLNWk3yqEQvF2= NHHxPZI3KGh? NV3zN3o5TE2VTx?= M3SyUYVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= M2eyN|I1QDh3MEiy
HepG2 NYTq[VM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{izRlczKGh? MlPrSG1UVw>? M17zO2lEPTB;M{WuPFYhyrFiMj65JO69VQ>? M1r5OlI1QDh2OEC5
HepG2/As MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXI[ndKPzJiaB?= M1HGWmROW09? MVnJR|UxRTZ6LkGzJOKyKDlwNjFOwG0> NUTDTlFPOjR6OES4NFk>
SMMC7721 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjMeI9[PzJiaB?= M33v[GROW09? M123U2lEPTB;M{GuNlghyrFiND6yJO69VQ>? MVGyOFg5PDhyOR?=
SMMC7721/Ac M3[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXFdow4OiCq M1XsVmROW09? MVrJR|UxRTV3LkKxJOKyKDVwMEOg{txO NX\W[215OjR6OES4NFk>
Huh-7 NXrxdmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n3[lczKGh? M4nFbGROW09? NYfYcolGUUN3ME2zN{46PiEEsTCzMlkh|ryP Ml;jNlQ5QDR6MEm=
Hep3B MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX2O|IhcA>? NWr3OGgzTE2VTx?= NFPOOHFKSzVyPUKwMlE5KMLzIEGuPFQh|ryP M3n2TlI1QDh2OEC5
HepG2 MVXBdI9xfG:|aYOgRZN{[Xl? MWLpcoR2[2W|IHHwc5B1d3Orcx?= NHHkd|gzPDh6NEiwPS=>
SMMC7721 NWHveYFvSXCxcITvd4l{KEG|c3H5 M2nNfIlv\HWlZYOgZZBweHSxc3nz MmXzNlQ5QDR6MEm=
Huh-7 NHH4WJRCeG:ydH;zbZMhSXO|YYm= NGrCWoZqdmS3Y3XzJIFxd3C2b4Ppdy=> NX;m[I43OjR6OES4NFk>
Hep3B MnrTRZBweHSxc3nzJGF{e2G7 MnfIbY5lfWOnczDhdI9xfG:|aYO= NG\GcmszPDh6NEiwPS=>
U2OS  NXfMNXd4TnWwY4Tpc44hSXO|YYm= MYCyNEDPxE1? M3nkdlI1KGh? NF\zN5FqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX M3j0V|I1QDZ5MkW5
AML2 NXH4VHJESXCxcITvd4l{KEG|c3H5 NXX1enB[Oi9zMDFOwG0> M{\DS|I1NzR6IHi= MUTpcoR2[2W|IHHwc5B1d3Orcx?= NF3PTpczPDZ3OUe0PS=>
MOML13 NYeyVJc2SXCxcITvd4l{KEG|c3H5 M{i2b|IwOTBizszN M2LZNlI1NzR6IHi= M4fxOYlv\HWlZYOgZZBweHSxc3nz MlfTNlQ3PTl5NEm=
AML2 NUj6OJQxTnWwY4Tpc44hSXO|YYm= MmnnNVDPxE1? MkDVNk81KGh? MoPtbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MmjnNlQ3PTl5NEm=
AML3 NF[4T3ZHfW6ldHnvckBCe3OjeR?= M1y2Z|Ex|ryP MYeyM|QhcA>? MYPpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NXT4WYg4OjR4NUm3OFk>
MOML13 NF7NbYtHfW6ldHnvckBCe3OjeR?= MlKwNVDPxE1? NYDlXY5FOi92IHi= M2H1colv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M3qzW|I1PjV7N{S5
BeWo MnTISpVv[3Srb36gRZN{[Xl? Mo[1N|AhyrWP MkfkNlQhcA>? M2\W[Ylv[3KnYYPld{BxPTNuIF3kcVItKHB{MTDhcoQhWHWvYTDheEB1cGVicILveIVqdiCuZY\lcC=> NH\1epozPDR7OEG1OC=>
BeWo M1HpemFxd3C2b4Ppd{BCe3OjeR?= NIXMSmo{OCEEtV2= NXXMOFJ6OjRiaB?= NVXUd3pjcW6lcnXhd4V{KGGyb4D0c5Nqew>? NUfPc|ZXOjR2OUixOVQ>
OCI NHf0cnpHfW6ldHnvckBCe3OjeR?= MnHvNVAh|ryP MYiyOEBp MlXUeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MViyOFQ4OzV4Mh?=
MOLM MkTnSpVv[3Srb36gRZN{[Xl? MVmxNEDPxE1? Mo\mNlQhcA>? MY\1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? MUCyOFQ4OzV4Mh?=
U2OS  MnfKSpVv[3Srb36gRZN{[Xl? NGHtfmUzOCEQvF2= MVuyOEBp MVfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NVvXdoM{OjR|Nk[wNFc>
RKO MnXnSpVv[3Srb36gRZN{[Xl? Mo\oNlAh|ryP MoexNlQhcA>? MWrpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NXXjeZR3OjR|Nk[wNFc>
U2OS  NUDQUVlpTnWwY4Tpc44hSXO|YYm= MmmzNlAh|ryP NWDWNYx7OjRiaB?= M1HaV4lv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u NX74TIsxOjR|Nk[wNFc>
RKO M3znSmZ2dmO2aX;uJGF{e2G7 M3nwS|IxKM7:TR?= MXyyOEBp NWLPNGcycW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MlXqNlQ{PjZyMEe=
SMMC-7721  NWHwXJFGS2WubDDWbYFjcWyrdImgRZN{[Xl? M2\aeFEvOjVvMkCg{txO NXXQTFkyOjRxNEivO|IhcA>? NFPGRolFVVOR Mnv4bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MYiyOFI5PjNzMh?=
HuH-7 MlvIR4VtdCCYaXHibYxqfHliQYPzZZk> MVyxMlI2NTJyIN88US=> MVOyOE81QC95MjDo MWrEUXNQ NUL0NFNqcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NUO4[nlDOjR{OE[zNVI>
SMMC-7721  NVWyTWtYSXCxcITvd4l{KEG|c3H5 NV3PdldVOjBizszN NF\tOYo1QCCq M3jPeWROW09? MV\pcoR2[2W|IHHwc5B1d3Orcx?= NXPpO2ZIOjR{OE[zNVI>
HuH-7 MVLBdI9xfG:|aYOgRZN{[Xl? NYLOWYtXOjBizszN Mn;GOFghcA>? MkXBSG1UVw>? MnK5bY5lfWOnczDhdI9xfG:|aYO= MkD1NlQzQDZ|MUK=
SMMC-7721  NH7UU3BHfW6ldHnvckBCe3OjeR?= NHH0em8yOCEQvF2= NIrNcHc{PiCq MYTEUXNQ Mn\o[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MmrLNlQzQDZ|MUK=
HuH-7 M4noTWZ2dmO2aX;uJGF{e2G7 M3fnc|ExKM7:TR?= M374SlM3KGh? NF;DdZdFVVOR MnLK[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> M1Xa[lI1Ojh4M{Gy
AT2 MlrKSpVv[3Srb36gRZN{[Xl? M2f2RVUwOTBizszN MXrs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MWmyOFI1ODJyMx?=
REH NWPWeXdMTnWwY4Tpc44hSXO|YYm= NHPCVVA2NzFyIN88US=> M2\2doxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NVvIOoVmOjR{NECyNFM>
UoCB6 Mn:wSpVv[3Srb36gRZN{[Xl? NWPNXYRZPS9zMDFOwG0> M{\jfYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NFnTbmIzPDJ2MEKwNy=>
AT2 M2noNWNmdGxiVnnhZoltcXS7IFHzd4F6 Moi5NE0zPSEQvF2= MoP5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NF\NZoczPDJ2MEKwNy=>
REH MkXIR4VtdCCYaXHibYxqfHliQYPzZZk> NHS5d24xNTJ3IN88US=> MonvbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MV2yOFI1ODJyMx?=
UoCB6 NGDEb3BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkXaNE0zPSEQvF2= M2HMVolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M2D3dFI1OjRyMkCz
A2780 NF\rPHJHfW6ldHnvckBCe3OjeR?= MmLjOU8yOC9{MDFOwG0> NX3iSG9COjRiaB?= MUD1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MVmyOFE{PjF2Nx?=
H460 NEnicZpHfW6ldHnvckBCe3OjeR?= M3\1TVUwOTBxMkCg{txO NInscJozPCCq NGXDNYN2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MX6yOFE{PjF2Nx?=
Lovo  MWHGeY5kfGmxbjDBd5NigQ>? MmToOU8yOC9{MDFOwG0> M1:4elI1KGh? NEW0Ump2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NH\5SHAzPDF|NkG0Oy=>
A2780 NVHlN2dDSXCxcITvd4l{KEG|c3H5 NFPHZmI2NzFyL{KwJO69VQ>? NWnoTZd1OjRiaB?= NWPSRZY{\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NYWyT41IOjRzM{[xOFc>
H460 M{XsUmFxd3C2b4Ppd{BCe3OjeR?= NF7r[pI2NzFyL{KwJO69VQ>? M{P6[VI1KGh? MmfX[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> M1jxdlI1OTN4MUS3
Lovo  MmnKRZBweHSxc3nzJGF{e2G7 MX61M|ExNzJyIN88US=> MnHwNlQhcA>? MUflcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> NFPyV|EzPDF|NkG0Oy=>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Related Antibodies

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID